secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001842952-22-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed
--------------------------------------------------------------------------------

- Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.
- Christopher Beck appointed SVP, Operations; previously VP of Program Management at Galera Therapeutics.
- Mark Fletcher, Ph.D., appointed VP, R&D; previously VP of Product Development at Pharmaceutical Associates, Inc.
- Appointments aim to advance lead candidate onapristone extended release (ONA-XR) in breast, ovarian, and endometrial cancers.
- Rencher's retirement was planned, not due to disagreement; advisory role continues through October 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/0001842952-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/cntx-20220101.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer